obesity

GLP-1 drugs like Ozempic and Wegovy were originally positioned as treatments for obese patients under medical care. A STAT analysis argues they are now marketed as lifestyle products for consumers seeking weight loss, cosmetic benefits and wellness, with telehealth platforms and direct-to-consumer advertising driving demand far beyond traditional clinical settings.

India has proposed banning junk food sales in school canteens and within 50 meters of schools, aiming to curb rising obesity and diabetes rates among children. The measures would restrict children's access to sugary drinks, chips and other unhealthy products during school hours and nearby, as health officials respond to growing concerns over childhood obesity across the country.

Efforts to ban ultra-processed foods from public schools are running into significant practical obstacles, according to reporting highlighted by News-Medical. Schools face challenges around sourcing affordable alternatives, reworking contracts with food suppliers, and meeting nutrition standards on tight budgets. The debate touches on children's health, obesity prevention, and the feasibility of overhauling cafeteria menus at scale.

New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.